- PULL subsidiary has submitted application to Health Canada to amend license to permit sales of product
- The submission follows recent announcement that Pure Extracts inked distribution agreement with an important Canadian Licensed Producer (“LP”)
- PULL plans on distributing exclusive vape, edible products to retail buyers across Canada
As a result of the its recently inked distribution agreement with an important Canadian LP, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) through its wholly owned subsidiary, Pure Extracts Manufacturing Corp., will be selling its exclusive, high-quality cannabis extract products to provincially authorized distributors and retailers throughout Canada by the end of April. The Company has also submitted an application to Health Canada to amend its license to permit the Company itself to sell cannabis extract products to provincially authorized distributors and retailers.
“This milestone dovetails perfectly with our recently signed distribution agreement,” said Pure Extracts’ CEO Ben Nikolaevsky. “We have all our bases covered now, and we will quickly and efficiently get our vape and edible products to retail buyers across Canada through our distribution partner while we wait to receive our own sales amendment from Health Canada.”
The distribution agreement calls for the LP to distribute Pure Extracts’ vape and edible products through its established provincial distribution channels. The agreement represents a significant opportunity to increase brand awareness and strengthen the sales for Pure Extracts’ Pure Pulls and Pure Chews branded products.
Currently, Pure Extracts’ portfolio of cannabis 2.0 products includes 34 proprietary formulations of Pure Pulls’ branded, full-spectrum oil (“FSO”) vape products and its new line of Pure Chews edible gummies (https://ibn.fm/tf7lt).
“We create products that are in high demand by provincially authorized distributors and retailers nationwide, and are looking forward to having our high-quality, FSO products in consumers’ hands early in Q2 of this year,” said Nikolaevsky.
Pure Extracts is also well positioned to partner with organizations planning to develop both functional and psychedelic products as the Company’s 10,000-square-foot facility is designed for EU-GMP certification, which allows for international sales. Pure Extracts has signed NDAs to explore joint development endeavors for product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc., the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies. The Company is positioned to be one of the dominant extraction companies and a leader in the rapid development and commercialization of functional and medicinal mushroom products.
For more information, visit the company’s website at www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL
